Morgan Stanley raised the firm’s price target on Cytokinetics (CYTK) to $71 from $65 and keeps an Overweight rating on the shares after the FDA approved the company’s Myqorzo with “a differentiated label and streamlined REMS.” The firm, which is “constructive” on Cytokinetics’ ability to execute a strong launch, sees near-term catalysts that could drive additional upside, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target raised to $83 from $73 at Leerink
- Cytokinetics price target raised to $95 from $87 at RBC Capital
- Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating
- Cytokinetics price target raised to $99 from $95 at Goldman Sachs
- Cytokinetics price target raised to $88 from $78 at Citizens